In addition, circulating IFNγ levels appeared to increase more gradually and in a less sustained manner in patients in cohorts B and C, compared with patients in cohort A with increased MAPK inhibitor-sensitive BRAF-mutant melanoma, even though the BRAF plus MEK inhibitor combination is expected to have less impact on wild type cells than the MEK inhibitor alone; a recognized paradoxical effect27. This evidence concerns the gene MAP2K7 and melanoma.